Trial Profile

Real life, multicenter study of edoxaban in elderly patients with atrial fibrillation

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 10 Feb 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Edoxaban (Primary) ; Vitamin K antagonists
Indications Atrial fibrillation; Stroke
Focus Adverse reactions; Therapeutic Use

Most Recent Events

14 Jun 2019 New trial record
28 May 2019 Primary end point (Safety outcome- major bleeding) was not met as per results published in the Clinical Therapeutics.
28 May 2019 Results published in the Clinical Therapeutics

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com